GlassScriptPhysician profile
Preeti Attavar
NPI 1497799217
$5,709.24
in general payments reported to CMS, 2019-2025
25 companies · $875 in 2025
The $875 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $698 · 2020: $237 · 2021: $847 · 2022: $899 · 2023: $1,113 · 2024: $1,041 · 2025: $875.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,009 · Education: $19.62.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,008.60 |
| Education | $19.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,213.74 | 2019-2025 | |
| Pfizer INC. | $477.92 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $393.59 | 2019-2025 | Eliquis, Camzyos |
| Boehringer Ingelheim Pharmaceuticals, INC. | $366.36 | 2019-2025 | Jardiance |
| Esperion Therapeutics, INC. | $336.48 | 2021-2024 | Nexletol |
| Abbott Laboratories | $323.28 | 2021-2025 | Cardiomems |
| Merck Sharp & Dohme LLC | $303.48 | 2021-2025 | Verquvo |
| Amgen INC. | $289.92 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $269.02 | 2019-2024 | |
| Janssen Pharmaceuticals, INC | $262.27 | 2019-2024 | Xarelto |
| Astrazeneca Pharmaceuticals LP | $190.66 | 2019-2025 | Farxiga |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $175.25 | 2019-2024 | Lifevest |
| Bayer Healthcare Pharmaceuticals INC. | $164.15 | 2021-2025 | |
| Lexicon Pharmaceuticals, INC. | $162.11 | 2023-2024 | Inpefa |
| Novo Nordisk INC | $143.66 | 2019-2025 | Wegovy, Rybelsus, Ozempic |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $122.66 | 2022-2025 | Watchman Access System, Lux-Dx Insertable Cardiac Monitor |
| Cvrx, INC. | $120.33 | 2022-2023 | Barostim Neo System |
| Medtronic, INC. | $107.68 | 2024 | Aurora Ev-Icd Mri Surescan |
| Alnylam Pharmaceuticals INC. | $62.61 | 2023 | Onpattro |
| Scpharmaceuticals INC. | $60.91 | 2023-2025 | |
| Vital Connect, INC | $52.04 | 2023-2024 | Vitalpatch Rtm |
| Regeneron Healthcare Solutions, INC. | $41.75 | 2019 | |
| Kiniksa Pharmaceuticals, LTD. | $36.76 | 2022-2023 | Arcalyst |
| Actelion Pharmaceuticals US, INC. | $17.85 | 2022 | |
| Amarin Pharma, INC. | $14.76 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Preeti Attavar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.